newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026

  • Cogent Biosciences will present preclinical data on its KRAS and ErbB2 pipeline programs at the AACR Annual Meeting 2026 in San Diego.
  • The company will showcase CGT1263, a pan-KRAS(ON) inhibitor with >500x selectivity for mutant KRAS over HRAS & NRAS, which may reduce skin toxicity compared to multi-RAS inhibitors.
  • Preclinical data for CGT1263 indicates sustained pERK inhibition & robust antitumor activity with limited skin suppression, supporting an IND submission expected later in 2026.
  • Cogent will present updates on CGT4255, a brain-penetrant ErbB2 inhibitor with >100x selectivity over EGFR & coverage of key mutations like YVMA, S310F, V842I, & L755S.
  • New data suggests CGT4255 has synergistic activity with HER2 ADCs, potentially enhancing receptor internalization, apoptosis, & re-sensitizing patients to resistance.
  • The Phase 1 study for CGT4255 is currently ongoing, while bezuclastinib is anticipated for potential commercial launch later this year.
  • Poster sessions for CGT1263 & CGT4255 are scheduled for April 19 & April 21, 2026, respectively, with details available on Cogent's website.